HIGHLIGHTS
- who: Suzanne V. Arnold from the MO, USA have published the Article: Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER, in the Journal: (JOURNAL)
- what: In a large, multinational, prospective cohort study of patients with type 2 diabetes, use of glucose-lowering medications with cardiovascular risk reduction has increased over time (particularly SGLT2i) but remains suboptimal.
SUMMARY
Prior to 2015, neither a strategy of intensive glucose control nor individual glucose-lowering medications had been successful in reducing cardiovascular risk in patients with . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.